Vicore Pharma AB
Executive Summary
Swedish start-up Vicore Pharma AB, in its attempts to address the inadequacies of current gastrointestinal therapies, claims that it is the only company focus on the gut-protecting properties of the angiotensin II type 2 (AT2) receptor, a heavily exploited drug target for CV indications.